Best GLP-1 telehealth: transparency first, then price
Updated 2026-08-10 · figures captured 2026-08-09 · how we verify
Price answers "how much"; telehealth quality answers "will this operate the way it claims." Since a pricing database cannot grade medicine, this ranking grades what is checkable: does the program name its pharmacies (the sharpest filter — most do not), publish a state list, state cancellation terms, include shipping and consultation, and price honestly at maintenance. Programs passing the most checks, then sorted by all-in price, produce the list below.
Standouts by structure: NexLife↗ (six named 503A/503B partner pharmacies, 50-state list, no membership, $215); Mochi (its own compounding facility and real video visits inside the $79 membership, $278 all-in); LifeMD↗ (50-state coverage and heavy clinical wrap, at a $597 price that buys it); on the brand side, Ro for insurance work and LillyDirect↗/NovoCare for manufacturer-direct simplicity. The vetting logic behind every check is documented here.
RANK01
NexLife
Dose-flat — the maintenance price equals the starter price; no membership fee; shipping included.
$215/MO ALL-IN
RANK02
Yucca Health
Dose-flat — the maintenance price equals the starter price; no membership fee; shipping included.
$258/MO ALL-IN
RANK04
Mochi Health
Dose-flat — the maintenance price equals the starter price; $79/mo membership already inside the figure; shipping included.
$278/MO ALL-IN
RANK06
Found
Dose-flat — the maintenance price equals the starter price; no membership fee; shipping included.
THIRD-PARTY REPORTED · captured 2026-08-05 · source · archive
$289/MO ALL-IN
RANK07
SkinnyRx
Dose-flat — the maintenance price equals the starter price; no membership fee; shipping included.
$299/MO ALL-IN
RANK08
OrderlyMeds
Dose-flat — the maintenance price equals the starter price; no membership fee; shipping included.
$299/MO ALL-IN
Programs failing multiple disclosure checks are not "bad," but they are unverifiable, and this list is for programs a careful reader can verify. The complete universe, flags and all, remains at /providers/.
The leaders, across a full year
Monthly figures flatter everyone equally; a year separates them. The field, annualized on the same all-in basis: NexLife: $2,580 monthly-billed, $2,232 on its prepaid path (upfront); Yucca Health↗: $3,096 monthly-billed; IVIM Health↗: $3,336 monthly-billed; Mochi Health↗: $3,336 monthly-billed; ShedRx: $3,468 monthly-billed; Found: $3,468 monthly-billed; SkinnyRx: $3,588 monthly-billed; OrderlyMeds↗: $3,588 monthly-billed.
Spread top-to-bottom within just these five: $1,008 a year — before considering the rest of the field, where the verified ceiling reaches $3,588. Prepaid paths shrink the totals and add commitment; the trade is priced properly in the annual-cost analysis and at your own numbers in the calculator.
Structure census across the 8 priced programs above: 6 are dose-flat, 6 carry no membership, 2 name their pharmacy network, and 1 publish a prepaid path below their own monthly-billed year. Those four counts are the shape of this list — the price column tells you what a program charges; the census tells you what kind of thing it is.
How to use a list like this well: shortlist two or three, pull each provider page, and read the record — structure, exit terms, pharmacy transparency, evidence flags — before letting the price column decide. The ranking gets you to the right neighborhood; the records keep you out of the wrong house.
Frequently asked
What is the cheapest option on this list?
NexLife at $215 per month all-in on the maintenance basis, captured 2026-08-10. Every figure here is medication plus mandatory fees; confirm at the provider's checkout before enrolling.
How is this ranking produced?
By sorting the public dataset on verified all-in monthly price at the maintenance dose — no editorial reordering, no paid placement. Basis, exclusions, and verification cycle: /methodology/; recompute it yourself from the JSON.
Are compounded GLP-1s on this page FDA-approved?
No compounded product is FDA-approved. Since 2025 compounded tirzepatide and semaglutide are limited to patient-specific 503A prescriptions with documented clinical need; brand options (Zepbound, Wegovy) are the approved products. Regulatory timeline: here.